Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Net Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Net Margin for 4 consecutive years, with 196.98% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 6258.0% to 196.98% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 241.96% through Dec 2025, down 14541.0% year-over-year, with the annual reading at 241.96% for FY2025, 14541.0% down from the prior year.
  • Net Margin for Q4 2025 was 196.98% at bioAffinity Technologies, up from 349.3% in the prior quarter.
  • The five-year high for Net Margin was 81.53% in Q1 2024, with the low at 427778.96% in Q3 2022.
  • Average Net Margin over 4 years is 45561.2%, with a median of 319.88% recorded in 2025.
  • Peak annual rise in Net Margin hit 42701145bps in 2023, while the deepest fall reached -207425bps in 2023.
  • Over 4 years, Net Margin stood at 71380.35% in 2022, then skyrocketed by 100bps to 107.22% in 2023, then decreased by -25bps to 134.4% in 2024, then tumbled by -47bps to 196.98% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 196.98%, 349.3%, and 319.88% for Q4 2025, Q3 2025, and Q2 2025 respectively.